X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (930) 930
Publication (92) 92
Book Review (3) 3
Newsletter (2) 2
Book Chapter (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (819) 819
hematology (619) 619
essential thrombocythemia (598) 598
index medicus (584) 584
female (446) 446
polycythemia-vera (425) 425
male (424) 424
oncology (411) 411
middle aged (368) 368
aged (345) 345
adult (318) 318
mutation (311) 311
janus kinase 2 - genetics (276) 276
myelofibrosis (261) 261
myeloproliferative disorders (243) 243
aged, 80 and over (202) 202
myeloproliferative neoplasms (179) 179
genetic aspects (174) 174
thrombocythemia, essential - genetics (168) 168
polycythemia vera (155) 155
tyrosine kinase jak2 (155) 155
diagnosis (152) 152
risk factors (145) 145
myeloproliferative disorders - genetics (141) 141
research (138) 138
tumors (134) 134
jak2 (133) 133
leukemia (130) 130
care and treatment (121) 121
thrombosis (119) 119
adolescent (113) 113
prognosis (113) 113
health aspects (105) 105
myeloid metaplasia (105) 105
polycythemia vera - genetics (105) 105
primary myelofibrosis (104) 104
polycythemia (101) 101
primary myelofibrosis - genetics (101) 101
thrombocytosis (101) 101
thrombocythemia (99) 99
thrombocythemia, essential - pathology (99) 99
analysis (91) 91
immunology (90) 90
medicine & public health (90) 90
thrombocythemia, essential - complications (90) 90
cancer (89) 89
gene mutations (89) 89
janus kinase 2 (87) 87
thrombocythemia, essential - diagnosis (84) 84
hydroxyurea (82) 82
hematology, oncology and palliative medicine (81) 81
patients (81) 81
disorders (80) 80
thrombocythemia, essential - drug therapy (80) 80
young adult (79) 79
animals (78) 78
bone marrow (76) 76
thrombocythemia, essential - blood (76) 76
myeloproliferative disorders - pathology (69) 69
stem cells (69) 69
myeloproliferative disorders - diagnosis (68) 68
chronic myeloproliferative disorders (67) 67
treatment outcome (67) 67
survival (66) 66
disease (65) 65
platelet count (64) 64
neoplasms (63) 63
idiopathic myelofibrosis (62) 62
primary myelofibrosis - pathology (62) 62
hemic and lymphatic diseases (61) 61
thrombocythemia, essential - immunology (60) 60
therapy (59) 59
retrospective studies (58) 58
jak2 v617f mutation (57) 57
risk (57) 57
calreticulin - genetics (56) 56
polycythemia vera - pathology (56) 56
receptors, thrombopoietin - genetics (56) 56
disease progression (55) 55
alleles (54) 54
development and progression (54) 54
international working group (54) 54
medical research (54) 54
myeloproliferative disorders - drug therapy (54) 54
child (53) 53
medicine, general & internal (53) 53
mice (53) 53
signal transduction (53) 53
article (52) 52
follow-up studies (52) 52
bone marrow - pathology (51) 51
janus kinase 2 - metabolism (51) 51
acute myeloid-leukemia (50) 50
medicine (50) 50
mutation - genetics (50) 50
essential thrombocythaemia (49) 49
pathology (49) 49
activating mutation (48) 48
primary myelofibrosis - diagnosis (48) 48
case-control studies (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (921) 921
French (3) 3
Italian (2) 2
Russian (2) 2
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 12, pp. 3359 - 3366
Journal Article
Leukemia, ISSN 0887-6924, 02/2018, Volume 32, Issue 2, pp. 429 - 437
The calreticulin (CALR) exon 9 mutations are found in similar to 30% of patients with essential thrombocythemia and primary myelofibrosis. Recently, we... 
POLYCYTHEMIA-VERA | ONCOLOGY | GENES | CLASS-I | NEOANTIGENS | ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | INTERFERON-ALPHA THERAPY | T-CELLS | CHRONIC MYELOPROLIFERATIVE NEOPLASMS | Exons - drug effects | Humans | Primary Myelofibrosis - immunology | HLA Antigens - immunology | Exons - genetics | Male | Vaccines, Subunit - immunology | HLA Antigens - genetics | Mutation - genetics | Thrombocythemia, Essential - genetics | Calreticulin - genetics | CD4-Positive T-Lymphocytes - immunology | Neoplasms - therapy | Phenotype | Primary Myelofibrosis - genetics | Vaccines, Subunit - therapeutic use | Mutation - drug effects | Neoplasms - genetics | Neoplasms - immunology | Thrombocythemia, Essential - immunology | HLA Antigens - drug effects | Aged | Cytotoxicity, Immunologic - drug effects | CD4-Positive T-Lymphocytes - drug effects | Usage | Gene mutations | Immunotherapy | Genetic aspects | Research | T cells | Health aspects | Cancer | Cell culture | Therapy | Target recognition | Toxicity | Vaccination | Cytotoxicity | Lymphocytes T | Hematopoietic stem cells | Cell recognition | Calreticulin | Lymphocytes | Autografts | Phenotypes | Myelofibrosis | Immune response | Epitopes | Patients | CD4 antigen | White blood cells | Monocytes | Dilution | Stem cells | Degranulation | Histocompatibility antigen HLA | Mutation | Human behavior
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2015, Volume 94, Issue 3, pp. 227 - 234
Journal Article
Journal Article
Experimental Hematology, ISSN 0301-472X, 2016, Volume 44, Issue 9, pp. 817 - 825.e3
Journal Article
European Journal of Haematology, ISSN 0902-4441, 04/2016, Volume 96, Issue 4, pp. 435 - 442
Journal Article
Leukemia Research, ISSN 0145-2126, 2012, Volume 36, Issue 11, pp. 1387 - 1392
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2017, Volume 23, Issue 9, pp. 1429 - 1436
Journal Article
Journal Article
Journal Article
Mediators of Inflammation, ISSN 0962-9351, 2015, Volume 2015, pp. 453020 - 13
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 9, pp. 1446 - 1454
Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV).... 
Hematology, Oncology and Palliative Medicine | Transplantation | PV | ET | MYELOFIBROSIS | RISK-FACTORS | MARROW | HYDROXYUREA | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | PHASE | MUTATION | CURATIVE THERAPY | JAK2 | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Myeloablative Agonists - therapeutic use | Recurrence | Humans | Middle Aged | Male | Graft vs Host Disease - immunology | Polycythemia Vera - mortality | Transplantation, Homologous | Splenectomy | Polycythemia Vera - complications | Splenomegaly - complications | Splenomegaly - therapy | Thrombocythemia, Essential - immunology | Splenomegaly - mortality | Adult | Female | Acute Disease | Splenomegaly - immunology | Neutrophils - immunology | Hematopoietic Stem Cell Transplantation | Polycythemia Vera - therapy | Thrombocythemia, Essential - mortality | Survival Analysis | Thrombocythemia, Essential - therapy | Graft vs Host Disease - prevention & control | Transplantation Conditioning | Longitudinal Studies | Polycythemia Vera - immunology | Thrombocythemia, Essential - complications | Autoimmunity | Medical colleges | Polycythemia | Oncology, Experimental | Bone marrow | Research | Hematopoietic stem cells | Biometry | Cancer | Splenomegaly | Neutrophils | Myeloablative Agonists | Thrombocythemia, Essential | Graft vs Host Disease | Life Sciences | Polycythemia Vera
Journal Article